Yahoo Web Search

Search results

    • MSD agrees to acquire EyeBio for up to $3bn

      MSD agrees to acquire EyeBio for up to $3bn

      Pharmaceutical Technology via Yahoo Finance· 2 days ago

      In March 2024, the European Commission approved MSD’s KEYTRUDA regimen for resectable non-small cell lung cancer (NSCLC) patients at increased recurrence...